Resources
57 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 4/26/2024
The Nitazenes Overview resource created by RCORP-TA describes what nitazenes are, how to determine if they are in your community, and how to prevent and respond to overdoses due to nitazenes. Additional resources are also provided to learn more about nitazenes.
Posted 4/16/2024 (updated 4/24/2024)
Adverse childhood experiences (ACEs) are events of abuse, neglect, and household dysfunction that occur between birth and 17 years of age. Multiple studies established the association between ACEs, risky behaviors, and poor physical and mental health outcomes in childhood and beyond. Rural and minority children often have higher rates of ACEs exposure than their peers.
Posted 2/20/2024 (updated 3/28/2024)
Early exposure to Adverse Childhood Experiences (ACEs), (e.g., parental substance use) increases the likelihood of future substance use and drug overdose, resulting in an intergenerational cycle of substance-related ACEs.
Posted 10/23/2023 (updated 3/27/2024)
The 2023 RCORP-CABH Onboarding Packet includes resources, tools, and strategies to support grant-funded activities, along with information on accessing TA. We hope you find the Onboarding Packet helpful as a starting point. Our TA team is here to support you through your grant, so should you have any questions related to this document or other technical assistance needs, please do not hesitate to contact your Technical Expert Lead (TEL).
Posted 10/23/2023 (updated 3/27/2024)
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/21/2023 (updated 3/28/2024)
The Office of National Drug Control Policy (ONDCP) released a plan in response to fentanyl being adulterated or associated with xylazine, which was declared as an emerging drug threat in April 2023. Due to the effect of combining these substances, people may be less responsive to naloxone in an overdose situation. The response plan includes evidence-based prevention, treatment, and supply reduction action steps, goals, and performance measures.